Trials that use: P-values
New to this method? Read the tutorial →
389 results
- KEYNOTE-024Independent statistical analysis of KEYNOTE-024 (NCT02142738), including randomized trial design, progression-free survival, overall survival, objective response rate, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-040Independent statistical analysis of KEYNOTE-040, a randomized phase 3 trial of pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell cancer, including overall survival, progression-free survival, response, statistical…
- KEYNOTE-045Independent statistical analysis of KEYNOTE-045, a randomized phase 3 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in advanced urothelial cancer, including primary and secondary endpoint results and statistical interpretation.
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-062Independent statistical analysis of KEYNOTE-062, a randomized phase 3 trial of pembrolizumab monotherapy and pembrolizumab plus standard chemotherapy in advanced gastric adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- KEYNOTE-119Independent statistical analysis of KEYNOTE-119, a randomized phase 3 trial comparing single-agent pembrolizumab with single-agent chemotherapy in metastatic triple negative breast cancer, including overall survival, response, progression-free survival, statistical methodology, and interpretation.
- KEYNOTE-177Independent statistical analysis of KEYNOTE-177, the randomized phase 3 trial of pembrolizumab versus standard of care in participants with MSI-H or dMMR stage IV colorectal carcinoma, covering PFS, overall survival, response, statistical…
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-355Independent statistical analysis of KEYNOTE-355, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- KEYNOTE-361Independent statistical analysis of KEYNOTE-361, the randomized phase 3 trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma, including primary and secondary endpoint analyses, statistical methods,…
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KEYNOTE-426Independent statistical analysis of KEYNOTE-426, the randomized phase 3 trial of pembrolizumab plus axitinib versus sunitinib monotherapy in renal cell carcinoma, including primary survival endpoints, response outcomes, statistical methodology, and interpretation.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-598Independent statistical analysis of KEYNOTE-598, a randomized phase 3 trial of pembrolizumab with ipilimumab versus pembrolizumab with placebo in untreated metastatic non-small cell lung cancer. Includes overall survival, progression-free survival, response, quality…
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-716Independent statistical analysis of KEYNOTE-716, a randomized phase 3 trial of pembrolizumab versus placebo in resected high-risk stage II melanoma, including trial design, recurrence-free survival, safety, statistical methodology, and interpretation.
- KEYNOTE-775Independent statistical analysis of KEYNOTE-775, evaluating lenvatinib plus pembrolizumab versus treatment of physician's choice in advanced endometrial cancer, with detailed interpretation of PFS, OS, response, quality-of-life, and statistical methods.
- KEYNOTE-811Independent statistical analysis of KEYNOTE-811, a randomized phase 3 trial of pembrolizumab plus trastuzumab and chemotherapy versus standard of care in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
- KEYNOTE-826Independent statistical analysis of KEYNOTE-826, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer.
- KEYNOTE-859Independent statistical analysis of KEYNOTE-859, a randomized phase 3 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric or gastroesophageal junction adenocarcinoma, including overall survival, progression-free survival, objective response rate,…
- KEYNOTE-966Independent statistical analysis of KEYNOTE-966, evaluating pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin for first-line advanced and/or unresectable biliary tract carcinoma.
- KEYNOTE-A18Independent statistical analysis of KEYNOTE-A18 (NCT04221945), a randomized phase 3 trial of chemoradiotherapy with or without pembrolizumab in locally advanced cervical cancer, including primary time-to-event results, secondary endpoints, cLDA, stratified analysis, and…
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.
- LEADERComplete statistical analysis of the LEADER phase 3 trial of liraglutide versus placebo in type 2 diabetes, including trial design, cardiovascular time-to-event endpoints, Cox regression, non-inferiority and superiority testing, secondary outcomes, safety,…
- LEAP-002Independent statistical analysis of LEAP-002, the randomized phase 3 trial of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line therapy in advanced hepatocellular carcinoma.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- LUX-Lung 8Independent statistical analysis of LUX-Lung 8, the phase 3 randomized trial of afatinib versus erlotinib in squamous cell lung cancer after at least one prior platinum-based chemotherapy. Includes progression-free survival, overall survival,…
- MA.17Independent statistical analysis of MA.17, a randomized phase 3 trial evaluating letrozole versus placebo in women with breast cancer who had received 5 years of aromatase inhibitor therapy, including disease-free survival, overall…
- MAGNITUDEIndependent statistical analysis of the phase 3 MAGNITUDE trial of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in castration-resistant prostate cancer, including rPFS, hazard ratios, confidence…
- MARIPOSAAn independent statistical analysis of the MARIPOSA phase 3 trial of amivantamab plus lazertinib versus osimertinib in locally advanced or metastatic non-small cell lung cancer, including trial design, progression-free survival methodology, results,…
- METEORIndependent statistical analysis of the METEOR phase 3 trial of cabozantinib versus everolimus in metastatic renal cell carcinoma, including progression-free survival, overall survival, objective response rate, trial design, and statistical methodology.
- MIRASOLIndependent statistical analysis of the MIRASOL phase 3 trial of mirvetuximab soravtansine versus investigator's choice chemotherapy in platinum-resistant advanced ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.
- ML18147Independent statistical analysis of ML18147, a randomized phase 3 trial of bevacizumab plus chemotherapy in metastatic colorectal cancer, including overall survival, progression-free survival, response rate, statistical methodology, safety, and interpretation.
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-3Independent statistical analysis of MONALEESA-3 (NCT02422615), a randomized phase 3 trial of ribociclib plus fulvestrant versus placebo plus fulvestrant in advanced breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MONARCH 2Independent statistical analysis of the MONARCH 2 phase 3 trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant, including trial design, progression-free survival, statistical methodology, interpretation, limitations, and safety.
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- MONARCH EIndependent statistical analysis of MONARCH E, the randomized phase 3 trial of abemaciclib plus standard adjuvant endocrine therapy versus endocrine therapy in breast cancer, including invasive disease-free survival, distant relapse-free survival, trial…
- MOVe-AHEADIndependent statistical analysis of the phase 3 MOVe-AHEAD trial of molnupiravir for prevention of Coronavirus Disease (COVID-19) in adults, including endpoint definitions, score-based confidence intervals, reported results, safety, and statistical interpretation.
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.
- NAVIGATE ESUSIndependent statistical analysis of NAVIGATE ESUS, a randomized phase 3 trial comparing rivaroxaban with aspirin in patients with recent embolic stroke of undetermined source, including time-to-event methods, primary and secondary results, safety,…
- NeoALTTOIndependent statistical analysis of the phase 3 NeoALTTO trial of lapatinib and trastuzumab in neoplasms of the breast, including pathological complete response, event-free survival, overall survival, landmark analyses, methodology, and interpretation.
- NIAGARAIndependent statistical analysis of the phase 3 NIAGARA trial of durvalumab plus gemcitabine/cisplatin in muscle invasive bladder cancer, covering pathologic complete response, event-free survival, secondary endpoints, methodology, and interpretation.
- NO16968Independent statistical analysis of NO16968 (NCT00069121), a randomized phase 3 trial of capecitabine plus oxaliplatin versus 5-FU/LV in colorectal cancer, including disease-free survival, relapse-free survival, overall survival, statistical methodology, and interpretation.
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…